[8-K] Xenon Pharmaceuticals Inc Reports Material Event
Xenon Pharmaceuticals Inc. announced via press release dated August 11, 2025 that it is furnishing its financial results for the three and six months ended June 30, 2025. The press release is attached as Exhibit 99.1 and, per the filing, the information is furnished to the SEC rather than filed.
The company reiterates that it distributes material information through SEC filings, press releases, conference calls, its corporate and investor websites, and social media channels. The filing identifies the company trading as XENE on the Nasdaq Global Market and is signed by Ian Mortimer, Chief Executive Officer and Interim Chief Financial Officer.
Xenon Pharmaceuticals Inc. ha annunciato con un comunicato stampa datato 11 agosto 2025 di fornire i risultati finanziari relativi ai tre e sei mesi chiusi al 30 giugno 2025. Il comunicato 猫 allegato come Exhibit 99.1 e, secondo il deposito, l'informazione 猫 fornita alla SEC anzich茅 presentata formalmente.
L'azienda ribadisce che distribuisce informazioni rilevanti tramite depositi alla SEC, comunicati stampa, conference call, i suoi siti aziendali e per gli investitori e i canali social. Il deposito indica che la societ脿 猫 quotata con il simbolo XENE sul Nasdaq Global Market ed 猫 firmato da Ian Mortimer, Chief Executive Officer e Interim Chief Financial Officer.
Xenon Pharmaceuticals Inc. anunci贸 mediante un comunicado de prensa fechado el 11 de agosto de 2025 que est谩 proporcionando sus resultados financieros correspondientes a los tres y seis meses terminados el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 y, seg煤n la presentaci贸n, la informaci贸n se proporciona a la SEC en lugar de ser formalmente presentada.
La compa帽铆a reitera que difunde informaci贸n relevante a trav茅s de presentaciones a la SEC, comunicados de prensa, conferencias telef贸nicas, sus sitios web corporativo y para inversores, y sus canales en redes sociales. La presentaci贸n identifica que la empresa cotiza con el s铆mbolo XENE en el Nasdaq Global Market y est谩 firmada por Ian Mortimer, Chief Executive Officer e Interim Chief Financial Officer.
Xenon Pharmaceuticals Inc.鞚� 2025雲� 8鞗� 11鞚�鞛� 氤措弰鞛愲毳� 韱淀暣 2025雲� 6鞗� 30鞚�搿� 膦呺霅� 3臧滌洈 氚� 6臧滌洈鞚� 鞛鞁れ爜鞚� 鞝滉车頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 氤措弰鞛愲電� Exhibit 99.1搿� 觳秬霅橃柎 鞛堨溂氅�, 鞝滌稖靹滌棎 霐半ゴ氅� 頃措嫻 鞝曤炒電� SEC鞐� 鞝滌稖(filed)霅橂姅 瓴冹澊 鞎勲媹霛� 鞝滉车霅橂姅 順曧儨鞛呺媹雼�.
須岇偓電� 欷戩殧頃� 鞝曤炒毳� SEC 鞝滌稖, 氤措弰鞛愲, 旎嵓霟办姢旖�, 須岇偓 氚� 韴瀽鞛� 鞗轨偓鞚错姼, 靻岇厹 氙鸽敂鞏� 毂勲剱鞚� 韱淀暣 氚绊彫頃滊嫟瓿� 鞛皑 臧曥“頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 須岇偓臧� 雮橃姢雼� 旮�搿滊矊 毵堨紦鞐愳劀 XENE搿� 瓯半灅霅滊嫟瓿� 旮办灛霅橃柎 鞛堨溂氅�, Ian Mortimer 斓滉碃瓴届榿鞛� 瓴� 鞛勳嫓 斓滉碃鞛毂呾瀯鞛愱皜 靹滊獏頄堨姷雼堧嫟.
Xenon Pharmaceuticals Inc. a annonc茅, par communiqu茅 de presse dat茅 du 11 ao没t 2025, qu'elle communiquait ses r茅sultats financiers pour les trois et six mois clos au 30 juin 2025. Le communiqu茅 est joint en tant que Exhibit 99.1 et, selon le d茅p么t, l'information est 肠辞尘尘耻苍颈辩耻茅别 脿 la SEC plut么t que d茅pos茅e formellement.
La soci茅t茅 r茅affirme qu'elle diffuse les informations importantes via les d茅p么ts aupr猫s de la SEC, les communiqu茅s de presse, les conf茅rences t茅l茅phoniques, ses sites web corporate et investisseurs, ainsi que ses canaux sur les r茅seaux sociaux. Le d茅p么t indique que la soci茅t茅 est cot茅e sous le symbole XENE sur le Nasdaq Global Market et est sign茅 par Ian Mortimer, Chief Executive Officer et Interim Chief Financial Officer.
Xenon Pharmaceuticals Inc. gab in einer Pressemitteilung vom 11. August 2025 bekannt, dass das Unternehmen seine Finanzergebnisse f眉r die drei und sechs Monate zum 30. Juni 2025 vorlegt. Die Pressemitteilung ist als Exhibit 99.1 beigef眉gt und laut Einreichung werden die Informationen an die SEC 眉产别谤尘颈迟迟别濒迟 statt formell eingereicht.
Das Unternehmen betont, dass es wesentliche Informationen 眉ber SEC-Einreichungen, Pressemitteilungen, Telefonkonferenzen, seine Unternehmens- und Investor-Websites sowie 眉ber Social-Media-Kan盲le verbreitet. Die Einreichung gibt an, dass das Unternehmen unter dem Ticker XENE am Nasdaq Global Market gehandelt wird und ist von Ian Mortimer, Chief Executive Officer und Interim Chief Financial Officer, unterzeichnet.
- None.
- None.
Insights
TL;DR Routine Form 8-K furnishing Xenon's Q2 2025 results; material details are in the attached press release (Exhibit 99.1).
The filing is procedural: it furnishes鈥攔ather than files鈥攖he Company's financial results for the three- and six-month periods ended June 30, 2025. No financial figures or operational details are included in the 8-K text itself, so material quantitative assessment requires reviewing Exhibit 99.1. The filing confirms the company鈥檚 chosen disclosure channels and reiterates Reg FD practices, which supports transparency of distribution but does not by itself change financial fundamentals.
TL;DR Standard disclosure practice observed; Exhibit 99.1 furnishes earnings information and Reg FD channels are restated.
The document follows routine 8-K procedures: reporting an earnings press release as furnished information and enumerating the company鈥檚 public disclosure channels, including SEC filings and social media. The form is signed by the CEO who also serves as Interim CFO, which is disclosed in the signature block. The filing contains no new governance actions, officer changes, or material transactions beyond the earnings release notification.
Xenon Pharmaceuticals Inc. ha annunciato con un comunicato stampa datato 11 agosto 2025 di fornire i risultati finanziari relativi ai tre e sei mesi chiusi al 30 giugno 2025. Il comunicato 猫 allegato come Exhibit 99.1 e, secondo il deposito, l'informazione 猫 fornita alla SEC anzich茅 presentata formalmente.
L'azienda ribadisce che distribuisce informazioni rilevanti tramite depositi alla SEC, comunicati stampa, conference call, i suoi siti aziendali e per gli investitori e i canali social. Il deposito indica che la societ脿 猫 quotata con il simbolo XENE sul Nasdaq Global Market ed 猫 firmato da Ian Mortimer, Chief Executive Officer e Interim Chief Financial Officer.
Xenon Pharmaceuticals Inc. anunci贸 mediante un comunicado de prensa fechado el 11 de agosto de 2025 que est谩 proporcionando sus resultados financieros correspondientes a los tres y seis meses terminados el 30 de junio de 2025. El comunicado se adjunta como Exhibit 99.1 y, seg煤n la presentaci贸n, la informaci贸n se proporciona a la SEC en lugar de ser formalmente presentada.
La compa帽铆a reitera que difunde informaci贸n relevante a trav茅s de presentaciones a la SEC, comunicados de prensa, conferencias telef贸nicas, sus sitios web corporativo y para inversores, y sus canales en redes sociales. La presentaci贸n identifica que la empresa cotiza con el s铆mbolo XENE en el Nasdaq Global Market y est谩 firmada por Ian Mortimer, Chief Executive Officer e Interim Chief Financial Officer.
Xenon Pharmaceuticals Inc.鞚� 2025雲� 8鞗� 11鞚�鞛� 氤措弰鞛愲毳� 韱淀暣 2025雲� 6鞗� 30鞚�搿� 膦呺霅� 3臧滌洈 氚� 6臧滌洈鞚� 鞛鞁れ爜鞚� 鞝滉车頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 氤措弰鞛愲電� Exhibit 99.1搿� 觳秬霅橃柎 鞛堨溂氅�, 鞝滌稖靹滌棎 霐半ゴ氅� 頃措嫻 鞝曤炒電� SEC鞐� 鞝滌稖(filed)霅橂姅 瓴冹澊 鞎勲媹霛� 鞝滉车霅橂姅 順曧儨鞛呺媹雼�.
須岇偓電� 欷戩殧頃� 鞝曤炒毳� SEC 鞝滌稖, 氤措弰鞛愲, 旎嵓霟办姢旖�, 須岇偓 氚� 韴瀽鞛� 鞗轨偓鞚错姼, 靻岇厹 氙鸽敂鞏� 毂勲剱鞚� 韱淀暣 氚绊彫頃滊嫟瓿� 鞛皑 臧曥“頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 須岇偓臧� 雮橃姢雼� 旮�搿滊矊 毵堨紦鞐愳劀 XENE搿� 瓯半灅霅滊嫟瓿� 旮办灛霅橃柎 鞛堨溂氅�, Ian Mortimer 斓滉碃瓴届榿鞛� 瓴� 鞛勳嫓 斓滉碃鞛毂呾瀯鞛愱皜 靹滊獏頄堨姷雼堧嫟.
Xenon Pharmaceuticals Inc. a annonc茅, par communiqu茅 de presse dat茅 du 11 ao没t 2025, qu'elle communiquait ses r茅sultats financiers pour les trois et six mois clos au 30 juin 2025. Le communiqu茅 est joint en tant que Exhibit 99.1 et, selon le d茅p么t, l'information est 肠辞尘尘耻苍颈辩耻茅别 脿 la SEC plut么t que d茅pos茅e formellement.
La soci茅t茅 r茅affirme qu'elle diffuse les informations importantes via les d茅p么ts aupr猫s de la SEC, les communiqu茅s de presse, les conf茅rences t茅l茅phoniques, ses sites web corporate et investisseurs, ainsi que ses canaux sur les r茅seaux sociaux. Le d茅p么t indique que la soci茅t茅 est cot茅e sous le symbole XENE sur le Nasdaq Global Market et est sign茅 par Ian Mortimer, Chief Executive Officer et Interim Chief Financial Officer.
Xenon Pharmaceuticals Inc. gab in einer Pressemitteilung vom 11. August 2025 bekannt, dass das Unternehmen seine Finanzergebnisse f眉r die drei und sechs Monate zum 30. Juni 2025 vorlegt. Die Pressemitteilung ist als Exhibit 99.1 beigef眉gt und laut Einreichung werden die Informationen an die SEC 眉产别谤尘颈迟迟别濒迟 statt formell eingereicht.
Das Unternehmen betont, dass es wesentliche Informationen 眉ber SEC-Einreichungen, Pressemitteilungen, Telefonkonferenzen, seine Unternehmens- und Investor-Websites sowie 眉ber Social-Media-Kan盲le verbreitet. Die Einreichung gibt an, dass das Unternehmen unter dem Ticker XENE am Nasdaq Global Market gehandelt wird und ist von Ian Mortimer, Chief Executive Officer und Interim Chief Financial Officer, unterzeichnet.
